The effect of 1,25-dihydroxyvitamin D3 on the cytoskeleton of rat calvaria and rat osteosarcoma (ROS 17/2.8) osteoblastic cells.
1,25-dihydroxyvitamin D3 produces pronounced shape changes in fetal rat calvaria and osteosarcoma-derived (ROS 17/2.8) osteoblastic cells, characterized by retracting processes and cell rounding followed by aggregation of cells. The 1,25(OH)2D3 effect on ROS 17/2.8 morphology was determined morphometrically on scanning electron micrographs. The hormone effect was found to be dose dependent between 10(-12) and 10(-9) M. The shape changes appeared 12 h after hormone (10(-10) M) addition and were present in 80% of the ROS 17/2.8 cells and in 50% of the calvaria cells at 72 h. Cycloheximide at 1 microM, inhibited the hormone-dependent change in morphology. The 1,25(OH)2D3 effects were partially mimicked by 10(-8) M 25(OH)D3 but not by 10(-10) M 25(OH)D3 or 10(-11)-10(-8) M 24,25(OH)2D3. 1,25-dihydroxyvitamin D3 also increased cell proliferation twofold at 14 days in serum-free medium. 1,25(OH)2D3 treatment produced changes in microfilament organization, visualized with rhodamine-conjugated phalloidin. Microfilaments were localized at the terminal attachment points and in the perinuclear region, and few if any, were seen in the retracting processes themselves. Estimation of cytoskeletal actin and myosin by gel electrophoresis of Triton X-100 nonextractable proteins showed a 30% reduction in these proteins in the hormone-treated cells. Microtubules visualized by indirect immunofluorescence showed no major changes in organization. Both colchicine and cytochalasin D altered the hormone-induced shape change, suggesting that both microfilaments and microtubules were required for this process. Thus, 1,25(OH)2D3 had pronounced effects on cell shape in osteoblastic cells, probably via de novo protein synthesis. These changes lead to rearrangement of the cytoskeleton, primarily the microfilaments.
Gronowicz
G
G
Department of Oral Biology, University of Connecticut Health Center, Farmington 06032.
Egan
J J
JJ
Rodan
G A
GA
D000199:Actins / Q000032:analysis; D000818:Animals; D001859:Bone Neoplasms / Q000648:ultrastructure*; D002117:Calcitriol / Q000494:pharmacology*; D002452:Cell Count; D002478:Cells, Cultured; D003078:Colchicine / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D015638:Cytochalasin D; D003572:Cytochalasins / Q000494:pharmacology; D003599:Cytoskeleton / Q000187:drug effects*; D005455:Fluorescent Antibody Technique; D008855:Microscopy, Electron, Scanning; D008870:Microtubules / Q000187:drug effects; D009218:Myosins / Q000032:analysis; D010006:Osteoblasts / Q000187:drug effects* / Q000473:pathology / Q000648:ultrastructure; D012516:Osteosarcoma / Q000648:ultrastructure*; D051381:Rats; D011919:Rats, Inbred Strains; D012886:Skull / Q000166:cytology / Q000187:drug effects* / Q000196:embryology; D014407:Tumor Cells, Cultured
D000199:Actins; D003572:Cytochalasins; D015638:Cytochalasin D; D003513:Cycloheximide; D009218:Myosins; D002117:Calcitriol; D003078:Colchicine